{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tamoxifen+20+mg", "query": { "intervention": "Tamoxifen 20 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 66, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tamoxifen+20+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T19:13:21.551Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05941520", "title": "Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Atypical Hyperplasia", "Breast Carcinoma", "Breast Ductal Carcinoma In Situ", "Breast Lobular Carcinoma In Situ" ], "interventions": [ { "name": "Acolbifene Hydrochloride", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Mammography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Random Periareolar Fine-Needle Aspiration", "type": "PROCEDURE" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "FEMALE", "summary": "35 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2024-10-10", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 4, "location_summary": "Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05941520" }, { "nct_id": "NCT02206984", "title": "Endocrine Response in Women With Invasive Lobular Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Priscilla McAuliffe", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 201, "start_date": "2015-09-30", "completion_date": "2024-07-19", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206984" }, { "nct_id": "NCT02228681", "title": "Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced, Persistent, or Recurrent Endometrial Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Medroxyprogesterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 74, "start_date": "2015-05-21", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 26, "location_summary": "Aurora, Colorado • Miami, Florida • Columbus, Georgia + 21 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Scarborough", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228681" }, { "nct_id": "NCT00229697", "title": "Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Gefitinib", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 317, "start_date": "2003-10", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2015-10-05", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 4, "location_summary": "Berkeley, California • Palm Springs, California • St Louis, Missouri + 1 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00229697" }, { "nct_id": "NCT00710970", "title": "Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seth Lerner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2007-01", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00710970" }, { "nct_id": "NCT00005908", "title": "Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasm" ], "interventions": [ { "name": "Docetaxel - Dose A", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel - Dose B", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Tamoxifen Citrate", "type": "DRUG" }, { "name": "Capecitabine - Dose B", "type": "DRUG" }, { "name": "Capecitabine - Dose A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2000-06", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2013-03-19", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005908" }, { "nct_id": "NCT00590785", "title": "Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High Risk", "Breast Cancer", "Positive Nodes", "Cyclophosphamide", "Doxorubicin" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "tamoxifen", "type": "DRUG" }, { "name": "ciprofloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 60, "start_date": "1996-08-13", "completion_date": "2015-01-13", "has_results": false, "last_update_posted_date": "2017-08-25", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00590785" }, { "nct_id": "NCT03528902", "title": "Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension", "Pulmonary Arterial Hypertension", "Familial Primary Pulmonary Hypertension", "Primary Pulmonary Hypertension", "Lung Diseases", "Tamoxifen", "Estrogen Receptor Antagonist", "Hormone Antagonists", "Estrogens" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-10-01", "completion_date": "2023-06-14", "has_results": true, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03528902" }, { "nct_id": "NCT03382834", "title": "Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Antiretroviral drugs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 31, "start_date": "2018-04-26", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03382834" }, { "nct_id": "NCT00756717", "title": "Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "MK-0752", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2008-02-14", "completion_date": "2011-12-21", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-09-29T19:13:21.551Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00756717" } ] }